The global automated immunoassay analyzers market size was USD 1.2 Billion in 2022 and is likely to reach USD 1.8 Billion by 2031, expanding at a CAGR of 5.5% during 2023–2031. The market growth is attributed to the rising demand for advanced diagnostic devices in the coming years.
Healthcare professionals and researchers use immunoassay to detect various types of antibodies; thus, it has significant applications in disease diagnosis, drug efficacy, clinical pharmacokinetics, therapeutic drug monitoring, bioequivalence studies, and pharmacodynamics in drug development. Their application is growing due to the accuracy of operations and the benefits of publishing tests.
As per the statistics published by the World Health Organization (WHO), chronic disease prevalence is increasing globally. In 2001, the number of chronic diseases was around 60%, from which 56.5 million reported deaths and 46% of the population suffering from the disease globally. Furthermore, the geriatric population is projected to increase up to 22% by 2050. Thus, immunoassay is expected to gain immense importance in the coming years, owing to applications in different fields, including clinical chemistry.
Apart from diagnostics, it has applications in process control, fertilizer analysis, seawater analysis, soil testing laboratories, air contaminants, and tobacco leaf analysis. Automated immunoassay analyzers are known for their sensitivity, criticalness, specificity, and rapid results.
The market report finds that the COVID-19 pandemic hindered the market, due to the strict lockdown imposed by the government. The pandemic has affected the immunoassay analyzers owing to the equipment demand and supply shortages, interruption of non-emergent medical services, and disruption of the supply chain which affected the market. However, the demand for efficient diagnostics solutions and the benefit of immunoassay analyzers for healthcare workers and patients as it allows the rapid, reliable, and low-cost detection of pathogens and viruses which boosts the market.
Artificial Intelligence (AI) Impact on Automated Immunoassay Analyzers Market
Artificial intelligence (AI) technologies are expected to boost the automated immunoassay analyzers market. Artificial intelligence offers reliable and flexible methods to manage data, workflows, and resources. Artificial intelligence helps scientists and technicians to analyze the implications of their experiments, develop alternative approaches to their projects, and design an effective project protocol. This alternative approach minimizes the time spent on repeating monotonous tasks. Immunoassay analyzers use AI to measure and locate the quantity of certain chemicals in a sample by using an antibody as a reagent. These tools are employed in clinical laboratories and hospitals and are capable of carrying out several tests, such as allergies, cancer, and other conditions.
Automated Immunoassay Analyzers Market Dynamics
Major Drivers
Increasing prevalence of chronic conditions, including cardiovascular disease, cancer, and diabetes mellitus is anticipated to boost the market during the forecast period. Immunoassays play an important role in disease diagnosis and treatment planning. Moreover, the introduction of technologically advanced automated immunoassay analyzers is another driving factor in the market.
- According to the American Diabetes Association, in 2021 around 38.4 million individuals, or 11.6% of the population have diabetes in the US.
Existing Restraints
Unavailability of healthcare providers and skilled professionals in developing regions is likely to hamper the market expansion in the coming years. Furthermore, the stringent regulations and high capital investments for the advancement of automated equipment is projected to hinder the market growth.
Emerging Opportunities
Rising disposable incomes and healthy government initiatives for providing effective healthcare facilities is expected to create lucrative opportunities for market players. Growing research and development activities in immunoassay analyzers testing and equipment further likely to offer abundant opportunities for market growth.
High demand for lab automation is expected to create lucrative opportunities for the market players. Several companies are investing in research and development activities to develop new innovative solutions and resolve the issues in the current product portfolio which increases the demand for the automated immunoassay analyzers market. Several biologics and pharmaceutical firms are highly using detection mechanisms for drug discovery and development purposes.
- In May 2023, Beckman Coulter Inc., launched the Dxl 9000 Access immunoassay Analyzer, the most productive immunoassay analyzer per footprint. This new analyzer boasts the industry’s highest throughput per footprint up to 215 tests per hour per square meter (tests/hr/m). It sets new expectations for immunoassay testing operational performance and the ability to develop and sustain better assay sensitivity to meet analytical needs.
Scope of the Automated Immunoassay Analyzers Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Automated Immunoassay Analyzers Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Application (Allergy Testing, Chronic Diseases, Drug Monitoring, Endocrinology, and Infectious Diseases), Product (Radioimmunoassay, Chemiluminescence, Enzyme Linked Fluorescent System, and Immunofluorescence), and End-user (Diagnostic Test Laboratories, Hospitals, Biotech and pharma companies, and Academic Research Institutes)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Meril Life Sciences; Abbott; Becton Dickinson and Company; Carolina Liquid Chemistries Corporation; Aesku Diagnostics; BioMerieux; BioRad; Perkin Elmer; Arlington Scientific; and Roche Diagnostics
|
Automated Immunoassay Analyzers Market Segment Insights
Application Segment Analysis
On the basis of application, the automated immunoassay analyzers market is segmented into allergy testing, chronic diseases, drug monitoring, endocrinology, and infectious diseases. The infectious diseases segment is anticipated to account for a significant market share during the forecast period, as they are caused by pathogenic microorganisms, such as viruses, bacteria, and parasites and they are highly communicable. Intensifying adoption of innovative molecular techniques coupled with rising government and non-profit organization intervention aiming to reduce the burden of infectious diseases, especially in developed and underdeveloped countries boosts the segment.
The drug monitoring segment is projected to expand at a considerable CAGR during the forecast period, due to rising research and drug development activities. Immunoassay has applications in clinical diagnostics and therapeutic drug monitoring.
Product Segment Analysis
Based on product, the market is divided into radioimmunoassay, chemiluminescence, enzyme linked fluorescent system, and immunofluorescence. The chemiluminescence segment is expected to hold a significant share of the market in the coming years, due to the high accuracy and sensitivity of the diagnosis using low analyte concentration. This immunoassay analyzer offers the identification of a hundred analytes per hour.
- In February 2023, Epitope Diagnostics, Inc. launched fully Automated Chemiluminescent immunoassay analyzers (ECL25 and ECL100). The ECL25 and ECL100 are fully automated, random-access chemiluminescent immunoassay systems that offer an all-in-one solution for both niche and routine clinical laboratory tests.
The radioimmunoassay segment accounts for a significant market share, owing to high reliability and receptiveness of this immunoassay. These assays are specific and sensitive. Additionally, it detects even few picograms of analyte in the experimental tube while using antibodies of high affinity.
End-user Segment Analysis
On the basis of end-user, the market is segregated into diagnostic test laboratories, hospitals, biotech and pharma companies, and academic research institutes. The hospitals segment is anticipated to expand at a substantial CAGR during the forecast period, due to the rising population of people who are suffering from lungs and heart related disorders. Furthermore, the presence of skilled professionals and equipped healthcare infrastructure is expected to boost the segment.
The diagnostic test laboratories segment is expected to hold a significant share of the market, due to facilitative schemes and availability of great care facilities. Advanced equipment for enhanced diagnostic testing including cardiac marker testing coupled with the helpful government schemes focusing on the reducing heart related disease burden is projected to propel the segment.
- According to the Centers for Disease Control and Prevention (CDC) in 2021, around 695,000 individuals died from heart disease in the US.
Regional Outlook
In terms of region, the global automated immunoassay analyzers market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period, owing to the rising prevalence of infectious diseases, various allergies, and cancer in the region. Moreover, supportive healthcare policies are projected to create lucrative opportunities for market players.
- According to the American Cancer Society in the US, around 1.9 million new cancer cases were diagnosed and 609,360 cancer deaths in 2022.
The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to the geriatric population in the region. Furthermore, the presence of healthcare expenditure and rising awareness regarding the early diagnosis of diseases. The high demand for diagnostics due to the rising prevalence of chronic diseases is likely to boost the market in the region.
Segments
The global automated immunoassay analyzers market has been segmented on the basis of
Application
- Allergy Testing
- Chronic Diseases
- Drug Monitoring
- Endocrinology
- Infectious Diseases
Product
- Radioimmunoassay
- Chemiluminescence
- Enzyme Linked Fluorescent System
- Immunofluorescence
End-user
- Diagnostic Test Laboratories
- Hospitals
- Biotech and pharma companies
- Academic Research Institutes
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global automated immunoassay analyzers market are Meril Life Sciences; Abbott; Becton Dickinson and Company; Carolina Liquid Chemistries Corporation; Aesku Diagnostics; BioMerieux; BioRad; Perkin Elmer; Arlington Scientific; and Roche Diagnostics.
Major companies in the market have adopted various organic growth strategies such as mergers, partnerships, product launches, and collaborations to increase their market share and achieve significant growth. Key players are actively involved in research and development programs and aim to expand their manufacturing units to increase their product portfolio and expand their consumer base. For instance,
-
In November 2021, Boditech Med, a company based in Korea, launched an Automated Immunoassay Analyzer with Blood Collection Tube. It has the unique capability of conducting 10 parallel tests for various parameter, which is expected to boost the company's revenue and industry presence in the coming years.
-
In September 2021, Thermo Fisher Scientific launched its fully-automated analyzers designed for enzyme assay applications. This analyzer systems combine new custom-designed software and hardware to offer fully automated incubation settings, reagent additions, and detailed measurement calculations. This development is playing a key role in expanding the company's product portfolio and driving business growth.
Request For Customization
Enquiry Before Buying
Speak With Analyst
